. . . . . "rac-Dobutamine"@en . . . . "2 minutes"@en . . . "Dobutaminum"@en . . . . . "approved"@en . . "For inotropic support in the short- term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures"@en . "Dobutamina"@en . . . . . . . "Dobutamine"@en . "34368-04-2"@en . . . . . . . . . "A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery."@en . . . . . . . "4-{2-[3-(4-hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol"@en . . . "Dobutamine"@en . . . " "@en . . . . "In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine."@en . . "R. R. Tuttle, J. Mills, DE 2317710 (1973). J. Mills, R. R. Tuttle, U.S. Patent 3,987,200 (1976)."@en . . . . "Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output."@en . . . . . . . . . . . . . . . . . . . . "Racemic-dobutamine"@en . . "Dobutamin"@en . . "DL-Dobutamine"@en . . "(+-)-4-(2-((3-(P-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol"@en . . " "@en . . "3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine"@en . . "Humans and other mammals"@en .